{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:17:21Z","timestamp":1793157441478,"version":"4.5.0"},"reference-count":58,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention & Research Institute of Texas","doi-asserted-by":"crossref","award":["RP190570"],"award-info":[{"award-number":["RP190570"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention & Research Institute of Texas","doi-asserted-by":"crossref","award":["RR150085"],"award-info":[{"award-number":["RR150085"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,12,11]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1\/PD-L1 therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The retrospective analysis includes clinical information from 767 patients with cancer treated at Hunan Cancer Hospital from 2017 to 2020. The pharmacovigilance data analysis includes individual cases of 38,705 safety reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2014 to 2020, and 25,122 cases of safety reports from the World Health Organization database VigiBase from 2014 to 2019. All cases that received anti-PD-1\/PD-L1 treatment were included. Multiomics data from patients across 25 cancer types were download from The Cancer Genome Atlas. Logistic regression and propensity score algorithm was employed to calculate OR of irAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Retrospective analysis of in-house patients showed that irAE potential risks are higher in all cancer (OR 2.12, 95%\u2009CI 1.38 to 3.22, false discovery rate (FDR) adjusted-p=1.93\u00d710<jats:sup>\u22123<\/jats:sup>) and patients with lung cancer (OR 3.16, 95%\u2009CI 1.67 to 5.95, FDR adjusted-p=1.93\u00d710<jats:sup>\u22123<\/jats:sup>) when using antibiotics. Potential risk of irAEs in patients with lung cancer with antibiotic treatment is significantly higher in FAERS (OR 1.39, 95%\u2009CI 1.21 to 1.59; FDR adjusted-p=1.62\u00d710<jats:sup>\u22125<\/jats:sup>) and VigiBase (OR 1.32, 95%\u2009CI 1.09 to 1.59, FDR adjusted-p=0.05). Mechanistically, decreased microbial diversity caused by antibiotics use may increase the irAE risk through mediating the irAE-related factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study is the first to comprehensively demonstrate the associations of irAEs and antibiotic during anti-PD-1\/PD-L1 therapy across a wide spectrum of cancers by analyzing multisource data. Administration of antibiotics should be carefully evaluated in patients with cancer treated by anti-PD-1\/PD-L1 to avoid potentially increasing irAE risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003779","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T10:42:39Z","timestamp":1642675359000},"page":"e003779","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":115,"title":["Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy"],"prefix":"10.1136","volume":"10","author":[{"given":"Ying","family":"Jing","sequence":"first","affiliation":[{"name":"Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyan","family":"Li","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-0634","authenticated-orcid":false,"given":"Steven H","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lou","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-2640","authenticated-orcid":false,"given":"Leng","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA"},{"name":"Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA"},{"name":"Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"2025100302394088000_10.1.e003779.1","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025100302394088000_10.1.e003779.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025100302394088000_10.1.e003779.3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100302394088000_10.1.e003779.4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30533-6"},{"key":"2025100302394088000_10.1.e003779.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"2025100302394088000_10.1.e003779.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100302394088000_10.1.e003779.8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100302394088000_10.1.e003779.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103"},{"key":"2025100302394088000_10.1.e003779.11","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jnci\/djaa057","article-title":"Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy","volume":"113","author":"Mohiuddin","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025100302394088000_10.1.e003779.13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0484-x"},{"key":"2025100302394088000_10.1.e003779.14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.trecan.2019.12.007","article-title":"The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy","volume":"6","author":"Ram\u00edrez-Labrada","year":"2020","journal-title":"Trends Cancer"},{"key":"2025100302394088000_10.1.e003779.15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.trecan.2020.01.004","article-title":"The cancer microbiome: distinguishing direct and indirect effects requires a systemic view","volume":"6","author":"Xavier","year":"2020","journal-title":"Trends Cancer"},{"key":"2025100302394088000_10.1.e003779.16","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Sepich-Poore","year":"2021","journal-title":"Science"},{"key":"2025100302394088000_10.1.e003779.17","first-page":"3195","article-title":"Antibiotic use does not appear to influence response to nivolumab","volume":"37","author":"Kaderbhai","year":"2017","journal-title":"Anticancer Res"},{"key":"2025100302394088000_10.1.e003779.18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint Inhibitor\u2013Related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/bib\/bbaa234","article-title":"Adverse events associated with potential drugs for COVID-19: a case study from real-world data","volume":"22","author":"Jing","year":"2021","journal-title":"Brief Bioinform"},{"key":"2025100302394088000_10.1.e003779.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13889-6"},{"key":"2025100302394088000_10.1.e003779.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025100302394088000_10.1.e003779.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2095-1"},{"key":"2025100302394088000_10.1.e003779.24","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","article-title":"Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden","volume":"5","author":"Bomze","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2025100302394088000_10.1.e003779.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw181"},{"key":"2025100302394088000_10.1.e003779.27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.8_suppl.131","article-title":"Biomarkers to predict immune-related adverse events with checkpoint inhibitors","volume":"37","author":"Head","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100302394088000_10.1.e003779.28","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025100302394088000_10.1.e003779.29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2025100302394088000_10.1.e003779.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.04.001"},{"key":"2025100302394088000_10.1.e003779.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y"},{"key":"2025100302394088000_10.1.e003779.32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100302394088000_10.1.e003779.33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7"},{"key":"2025100302394088000_10.1.e003779.34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"ClusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS: A J of Integrative Biology"},{"key":"2025100302394088000_10.1.e003779.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.006"},{"key":"2025100302394088000_10.1.e003779.36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100302394088000_10.1.e003779.37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.annonc.2021.08.1744","article-title":"Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy","volume":"32","author":"Cortellini","year":"2021","journal-title":"Ann Oncol"},{"key":"2025100302394088000_10.1.e003779.38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002421"},{"key":"2025100302394088000_10.1.e003779.39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0484-x"},{"key":"2025100302394088000_10.1.e003779.40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321"},{"key":"2025100302394088000_10.1.e003779.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32317-7"},{"key":"2025100302394088000_10.1.e003779.42","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/cid\/ciy711","article-title":"Detrimental effect of broad-spectrum antibiotics on intestinal microbiome diversity in patients after allogeneic stem cell transplantation: lack of commensal sparing antibiotics","volume":"68","author":"Weber","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025100302394088000_10.1.e003779.43","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","article-title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","volume":"30","author":"Elkrief","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100302394088000_10.1.e003779.44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236"},{"key":"2025100302394088000_10.1.e003779.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2971-8"},{"key":"2025100302394088000_10.1.e003779.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0238-9"},{"key":"2025100302394088000_10.1.e003779.47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jamaoncol.2019.0450","article-title":"Real-world evidence - what does it really mean?","volume":"5","author":"Nabhan","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.011"},{"key":"2025100302394088000_10.1.e003779.49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.50","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0484-x"},{"key":"2025100302394088000_10.1.e003779.51","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0484-x"},{"key":"2025100302394088000_10.1.e003779.52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2764"},{"key":"2025100302394088000_10.1.e003779.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1969-6"},{"key":"2025100302394088000_10.1.e003779.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.001"},{"key":"2025100302394088000_10.1.e003779.55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat Commun"},{"key":"2025100302394088000_10.1.e003779.56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","article-title":"Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy","volume":"1","author":"Ye","year":"2019","journal-title":"Nat Metab"},{"key":"2025100302394088000_10.1.e003779.57","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302394088000_10.1.e003779.58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay9189"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:39:50Z","timestamp":1759484390000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,20]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jitc-2021-003779"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003779","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}